NuVasive shared its 2017 fourth quarter and full-year financial results.
Here are results from the fourth quarter 2017.
1. The company's revenue was flat at $271.7 million, compared to 2016.
2. NuVasive saw international revenue growth of 34 percent on a constant currency basis.
3. GAAP operating profit margin was 11 percent, and non-GAAP operating was 18.2 percent.
4. NuVasive's GAAP diluted earnings per share were $0.46, with non-GAAP diluted EPS increasing 5.7 percent.
Here are the company's full-year 2017 financial results.
5. NuVasive's revenue saw a 7 percent boost to $1.03 billion.
6. The GAAP operating profit margin was 11 percent, with a non-GAAP operating profit margin of 16.6 percent.
7. The company's GAAP diluted EPS was $1.50, and non-GAAP diluted EPS was $1.91.
8. NuVasive reported net income of $99.9 million, compared to $86.5 million in 2016, on a non-GAAP basis.
9. As of Dec. 31, 2017, NuVasive's cash and cash equivalents were about $72.8 million.
For 2018, NuVasive expects revenue between $1.095 billion and $1.105 billion.
"As we set the stage for 2018, we remain focused on accelerating our growth momentum by furthering our investment in R&D to bring innovative offerings to the market, developing our differentiated intraoperative neurophysiological monitoring services business with the completed acquisition of SafePassage and growing the number of surgeons worldwide who use NuVasive technologies to improve patients' quality of life," said NuVasive Chairman and CEO Gregory T. Lucier.